菲律宾成为第一个批准登革热疫苗的亚洲国家（中英双语）
青岛希尼尔翻译咨询有限公司（www.sinosenior.com）整理发布 2015-12-24
青岛希尼尔翻译公司（www.sinosenior.com）2015年12月24日了解到：（巴黎）本周四，菲律宾宣布批准世界上首个登革热疫苗在国内销售，成为第一个批准该疫苗的亚洲国家。Paris
(AFP) - The Philippines became the first Asian country on Tuesday to
approve the sale of the world’s first-ever dengue vaccine.
Dengvaxia, manufactured by French pharmaceutical giant Sanofi, secured
its first regulatory approval in Mexico a fortnight ago and is currently
being reviewed by around 20 countries in Asia and Latin America.
两周前，由法国制药巨头赛诺菲研发的Dengvaxia在墨西哥获得批准通过，并且在近期由20个亚洲和拉丁美洲国家审核。
It is hoped the drug could eventually help prevent millions of deaths
from dengue, the world’s fastest-growing mosquito-borne disease.
人们希望这种药物最终能够帮助上百万人脱离登革热的死亡威胁。登革热是世界上扩散速度最快的蚊媒疾病。
The World Health Organization says as many as 400 million people are
infected worldwide every year, and two-thirds are in Asia.
世界卫生组织说，全球每年都有4亿人感染登革热，其中三分之二的患者身处于亚洲。
"It’s a major step in the prevention of dengue and for public health,"
Olivier Charmeil, head of Sanofi’s vaccines division, said in a
statement.
赛诺菲疫苗事业部的部长Olivier Charmeil在声明中写道：“这是预防登革热和维护公共健康的重要一步。”
Scientists have long been stumped by dengue, which has four separate
strains, forcing researchers to find a drug able to fight all of them at
once.
科学家们曾长期为登革热所困惑。登革热有四种分离的菌株，这迫使研究人员去寻找能够一次杀灭所有菌株的药物。
Clinical tests -- carried out on 40,000 people from 15 countries --
have found Dengvaxia can immunise two-thirds of people aged nine years
and older, rising to 93 percent for the more severe form of the disease,
dengue haemorrhagic fever.
来自15个国家的4万人参与的临床测试发现，Dengvaxia能够让三分之二九十岁甚至更年长的人对登革热免疫，使他们有93%的几率不会患上登革出血热。登革出血热是登革热中最严重的一种。
It was also found to reduce the risk of hospitalisation by 80 percent.
该疫苗同样被验证能够将住院几率降低80%。
Dengue can trigger a crippling fever, along with muscle and joint
pain. There is no known cure, and children are at particular risk.
登革热能够引发造成患者身体受损的高烧，并伴有肌肉和关节疼痛。目前还未有明确的疗法。孩童是该病的高危人群。
The deadliest form of the disease kills 22,000 people a year, the WHO
says.
世界卫生组织称，该病最猛烈的一种能在一年内夺取2万2千人的生命。
It was once considered a disease of the tropics, endemic in only nine
countries, but globalisation, urbanisation, climate change and jet
travel are helping it to move into more temperate zones.
登革热曾一度被看做是热带疾病，只会在九个国家中传染。但是全球化、城市化、气候变化、以及航空飞行让其进入了更多的温带地区。
It is now endemic in more than 100 countries.
如今登革热已成为超过100个国家的地方性流行病。
The WHO says cases have risen 30-fold over the last 50 years, with
more than half the world’s population potentially at risk.
世界卫生组织称，最近50年来，登革热病例数已经增长近30倍，超过世界半数人口都有潜在的患病危险。
Several million doses of the vaccine are ready to ship, and Sanofi
expects annual production to reach 100 million doses by 2017.
赛诺菲已准备好用于船运的几百万剂疫苗，并期望到2017年疫苗的年生产量能够到达一亿剂。
Sanofi’s research and development work took 20 years, costing more
than 1.5 billion euros ($1.6 billion).
赛诺菲用了20年来研究制药，整个过程花费超过15亿欧元（16亿美金）。
But the vaccine could bring the company more than $1 billion annually
starting in 2018 or 2019, analysts said.
分析人员称，这种疫苗能在2018年或2019年开始给赛诺菲带来每年超过10亿美金的收入。
Other pharmaceutical companies are developing dengue vaccines,
including US firm Merck, Japan’s Takeda and Britain’s GlaxoSmithKline,
but Sanofi is ahead of the competition.
其他制药公司也在研制登革热疫苗，这其中包括美国的默克公司、日本的武田制药，还有英国的葛兰素史克公司。然而赛索菲在研制竞赛中拨得头筹。
来源:雅虎新闻
注：部分新闻来源于网路，如有涉及版权，请及时通知我们，我们将尽快删除。
---------------------------------------------------------------------------------------------------------------------------------------------------------------